Apolipoprotein A I/APOA1 Antibody (464CT10.4.4): sc-517307

apoA-I Antibody (464CT10.4.4) is a mouse monoclonal IgG1 antibody that detects apolipoprotein A-I (apoA-I) in mouse, rat, and human samples through western blotting (WB). apoA-I is a crucial component of high-density lipoprotein (HDL) in plasma, consisting of a single chain of 243 amino acids that plays a vital role in cholesterol metabolism by promoting the efflux of cholesterol from peripheral tissues to the liver for excretion. This process is essential for maintaining lipid homeostasis and preventing atherosclerosis, a condition characterized by the buildup of fats, cholesterol, and other substances in and on the artery walls. Additionally, apoA-I serves as a cofactor for lecithin cholesterol acyltransferase (LCAT), an enzyme that catalyzes the formation of cholesteryl esters, further facilitating the transport and metabolism of lipids. apoA-I′s ability to influence plasma lipid levels underscores its importance in cardiovascular health, making apoA-I a significant target for research in lipid disorders and related diseases. anti-apoA-I antibody (464CT10.4.4) is an invaluable tool for researchers investigating the roles of apolipoproteins in lipid metabolism and cardiovascular disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Apolipoprotein A I/APOA1 Antibody (464CT10.4.4) References:

1. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.  |  Van Lenten, BJ., et al. 2008. J Lipid Res. 49: 2302-11. PMID: 18621920
2. Apolipoprotein A-I (ApoA-I) mimetic peptide P2a by restoring cholesterol esterification unmasks ApoA-I anti-inflammatory endogenous activity in vivo.  |  Bucci, M., et al. 2012. J Pharmacol Exp Ther. 340: 716-22. PMID: 22171091
3. An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.  |  Lu, SC., et al. 2012. J Lipid Res. 53: 643-52. PMID: 22287724
4. Altered expression of apoA-I, apoA-IV and PON-1 activity in CBS deficient homocystinuria in the presence and absence of treatment: possible implications for cardiovascular outcomes.  |  Jiang, H., et al. 2012. Mol Genet Metab. 107: 55-65. PMID: 22633282
5. Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL.  |  Fotakis, P., et al. 2013. J Lipid Res. 54: 3293-302. PMID: 24123812
6. ApoA-I Milano stimulates lipolysis in adipose cells independently of cAMP/PKA activation.  |  Lindahl, M., et al. 2015. J Lipid Res. 56: 2248-59. PMID: 26504176
7. The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration.  |  Nowacki, TM., et al. 2016. Br J Pharmacol. 173: 2780-92. PMID: 27425846
8. Development of anti-chloro 192 tyrosine HDL apoA-I antibodies for the immunodiagnosis of cardiovascular diseases.  |  Lokeshwaran, K., et al. 2019. J Immunol Methods. 474: 112637. PMID: 31386835
9. The effect of the content of ApoA-I in peripheral blood on the state of immune homeostasis in people living in extreme climatic conditions of the Arctic.  |  Pashinskaya, KO., et al. 2021. Klin Lab Diagn. 66: 539-545. PMID: 34543532
10. ApoA-I Nanoparticles as Curcumin Carriers for Cerebral Endothelial Cells: Improved Cytoprotective Effects against Methylglyoxal.  |  Narra, SS., et al. 2022. Pharmaceuticals (Basel). 15: PMID: 35337146

The preferred Apolipoprotein A I/APOA1 antibody is Apolipoprotein A I/APOA1 Antibody (B-10): sc-376818.